GeoVax Labs (GOVX) vs Virax Biolabs Group (VRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GeoVax Labs is the larger company by market cap ($2.9 million vs $2.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GOVX | VRAX |
|---|---|---|
| Share price | $0.2866 | $1.99 |
| Market cap | $2.90M | $2.68M |
| 1-day change | -0.97% | -5.69% |
| EPS (TTM) | $-8.70 | $-11.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.75 | $21.75 |
| 52-week low | $0.277 | $1.83 |
| Distance from 52-week high | -98.18% | -90.85% |
| Analyst consensus | none | — |
| Avg. price target upside | +3389.18% | — |
| Average volume | 771.47K | 650.11K |
| Shares outstanding | 10.10M | 1.34M |
| Employees | 19 | 26 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About GeoVax Labs
GOVX stock →GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
Healthcare · Biotechnology · 19 employees
About Virax Biolabs Group
VRAX stock →Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease.
Healthcare · Biotechnology · 26 employees
GOVX vs VRAX FAQ
Which is bigger, GeoVax Labs or Virax Biolabs Group?
GeoVax Labs (GOVX) is larger, with a market capitalization of $2.90M compared with $2.68M for Virax Biolabs Group (VRAX).
Are GeoVax Labs and Virax Biolabs Group in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.